Insulin sensitivity vs insulin secretion — how GLP-1 agonists differ from insulin

This is so encouraging. I'm 38F with PCOS and a HOMA-IR of 4.8. I've been on metformin for 2 years with minimal improvement. My endo is considering adding tirzepatide. How quickly did you notice the HOMA-IR starting to drop? And did you have any issues with the nausea during titration?

The HOMA-IR improvement was noticeable by month 3 (from 9.5 to 5.6 — a 41% reduction in just 3 months). That early improvement was likely driven partly by reduced caloric intake and early weight loss, and partly by tirzepatide's direct insulin-sensitizing effects.

As for nausea: yes, I had moderate nausea during the first 2 months, particularly during dose escalations. It was manageable with small frequent meals and ginger tea. By month 3 it was minimal and by month 4 it was gone entirely. The titration schedule exists for a reason — the slow escalation makes a huge difference.

I want to underscore one more thing about HOMA-IR tracking: it can predict who is at risk for weight regain and metabolic relapse if they discontinue therapy.

Patients whose HOMA-IR normalizes and remains <2.0 on a stable dose tend to have better long-term metabolic outcomes even if they eventually reduce their dose. Patients whose HOMA-IR improves but remains >3.0 despite significant weight loss may have a more "fixed" insulin resistance phenotype (possibly genetic) and may require indefinite therapy.

I use HOMA-IR as one of my decision points when patients ask about dose reduction or discontinuation. If HOMA-IR is <2.0, the metabolic machinery is working properly and there may be more room to taper. If it's still elevated, stopping is riskier.

Exceptional thread. The longitudinal HOMA-IR tracking combined with clinical outcomes (PCOS improvement, diabetes prevention) makes this a valuable reference for the community. Pinned.